J&J Unit Under Scrutiny For Alleged Off-Label Marketing

Law360 (August 8, 2006, 12:00 AM EDT) -- Johnson & Johnson said in a U.S. Security and Exchange Commission filing Tuesday that one of its subsidiaries has received a subpoena related to the alleged off-label marketing of its epilepsy and migraine drug Topamax.

J&J said it was cooperating with the recent subpoena, which it received in June.

This is not the first time the company has come under fire for alleged off-label marketing of the drug.

In December 2003, J&J subsidiary Ortho-McNeil Pharmaceutical Inc. received its first subpoena from the U.S. Attorney’s Office for...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.